Vitamin D supplementation has no effect on conventional cardiovascular risk factors:A parallel-group, double-blind, placebo-controlled RCT

Wood, Adrian D., Secombes, Karen R., Thies, Frank, Aucott, Lorna, Black, Alison J., Mavroeidi, Alexandra, Simpson, William G., Fraser, William D., Reid, David M. and Macdonald, Helen M. (2012) Vitamin D supplementation has no effect on conventional cardiovascular risk factors:A parallel-group, double-blind, placebo-controlled RCT. The Journal of Clinical Endocrinology and Metabolism, 97 (10). pp. 3557-3567. ISSN 0021-972X

Full text not available from this repository. (Request a copy)

Abstract

Context: Observational studies show an association between low vitamin D status assessed by circulating 25-hydroxyvitamin D and cardiovascular events and mortality. Data from randomized controlled trials are limited. Objective: The aim of this study was to test whether daily doses of vitamin D at 400 or 1000 IU/d for 1 yr affected conventional markers of cardiovascular disease (CVD) risk. Design: We conducted a parallel-group, double-blind, placebo-controlled randomized controlled trial. Randomization was computer generated. Participants and study investigators were blinded to intervention groupings throughout the trial. Setting: The study was conducted at the Clinical Research Facility, University of Aberdeen, United Kingdom. Participants: Atotal of 305 healthy postmenopausal women aged 60-70 yr were recruited for the study. Intervention: Each woman received a daily capsule of 400 or 1000 IU vitamin D3 or placebo randomly allocated. Main Outcome Measures: Primary outcomes were serum lipid profile [total, high-density lipoprotein, and low-density lipoprotein cholesterol; triglycerides; and apolipoproteins A-1 and B ], insulin resistance (homeostatic model assessment), inflammatory biomarkers (high-sensitivity C-reactive protein, IL-6, soluble intracellular adhesion molecule-1), and blood pressure. Results: Atotal of 265 (87%) participants completed all study visits. Small differences between groups for serum apolipoprotein B change [repeated measures ANOVA, P = 0.04; mean (SD), -1.0 (10.0) mg/dl (400 IU); -1.0 (10.0) mg/dl (1000 IU); and +0.02 (10.0) mg/dl (placebo)] were not considered clinically significant. Other systemic markers for CVD risk remained unchanged. There was significant seasonal variation in systolic and diastolic blood pressure independent of vitamin D dose (P

Item Type: Article
Uncontrolled Keywords: aged,biological markers,cardiovascular diseases,cholecalciferol,double-blind method,female,humans,middle aged,placebos,postmenopause,risk factors,risk reduction behavior,vitamins
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Related URLs:
Depositing User: Pure Connector
Date Deposited: 24 Sep 2013 01:00
Last Modified: 21 Apr 2020 21:55
URI: https://ueaeprints.uea.ac.uk/id/eprint/43419
DOI: 10.1210/jc.2012-2126

Actions (login required)

View Item View Item